Last reviewed · How we verify
Keto Acid
Keto acid provides essential amino acids and nitrogen-sparing substrates to support protein synthesis and reduce protein catabolism in patients with renal or hepatic disease.
Keto acid provides essential amino acids and nitrogen-sparing substrates to support protein synthesis and reduce protein catabolism in patients with renal or hepatic disease. Used for Chronic kidney disease with protein-energy wasting, Hepatic encephalopathy, Uremia management in dialysis patients.
At a glance
| Generic name | Keto Acid |
|---|---|
| Also known as | Compound α-Ketoacid Tablets |
| Sponsor | Peking University First Hospital |
| Drug class | Amino acid supplement / Nutritional agent |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Hepatology / Nutrition support |
| Phase | FDA-approved |
Mechanism of action
Keto acids are branched-chain amino acid analogs that serve as nitrogen-free precursors for endogenous amino acid synthesis. By providing these substrates, keto acid therapy reduces the nitrogen load on compromised kidneys or liver while maintaining amino acid availability for protein synthesis, thereby improving nutritional status and reducing uremic toxin accumulation in chronic kidney disease or hepatic encephalopathy.
Approved indications
- Chronic kidney disease with protein-energy wasting
- Hepatic encephalopathy
- Uremia management in dialysis patients
Common side effects
- Gastrointestinal upset
- Nausea
- Taste disturbance
Key clinical trials
- Effect of Nutritional Ketosis on Alcohol Metabolism (PHASE2, PHASE3)
- Ketogenic Diet Interventions in Parkinson's Disease: Safeguarding the Gut Microbiome (NA)
- Low-cost Screening and Image-guided Photodynamic Therapy (PDT) of Premalignant and Malignant Oral Lesions (PHASE2)
- Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma (PHASE2)
- A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) (PHASE2)
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid（5-ALA） (PHASE3)
- Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Keto Acid CI brief — competitive landscape report
- Keto Acid updates RSS · CI watch RSS
- Peking University First Hospital portfolio CI